Abstract：
OBJECTIVE: To compare the diagnostic performance of CEUS-guided biopsy (CEUS-GB) and ultrasound-guided biopsy (US-GB) in evaluating abdominal and pelvic (abdominopelvic) neoplasms in paediatric patients.
METHODS: Patients aged < 18 years with abdominopelvic tumours who underwent either CEUS-GB or US-GB between April 2005 and May 2022 were retrospectively evaluated. Tumours diagnosed as malignancies by pathology were considered true-positive findings. Benign lesions were identified by pathology or clinical follow-up of at least 6 months. The diagnostic performance of the two groups was compared using propensity score matching (PSM). Complications were also analysed.
RESULTS: The present study included 764 paediatric patients (437 boys; median age, 24 months; interquartile range, 10-60 months); 151 were in the CEUS-GB group, and 613 were in the US-GB group. The sample adequacy rate was 100% (151 of 151) for the CEUS-GB group, which was greater than the 97.4% (597 of 613) for the US-GB group (p < 0.001). The overall diagnostic accuracy of the CEUS-GB group and US-GB group was 98.7% (149 of 151) versus 97.3% (581 of 597) in the total cohort (p = 0.551) and 98.7% (149 of 151) versus 92.7% (140 of 151) in the PSM cohort (p = 0.020). Two patients (0.3%) in the US-GB group experienced complications (Common Terminology Criteria for Adverse Events (CTCAE), grade 1-2) correlated with the biopsy. No adverse reactions occurred in the CEUS-GB group.
CONCLUSIONS: CEUS-GB of abdominopelvic tumours in paediatric patients is an effective and safe procedure with greater diagnostic accuracy than US-GB, especially for tumours with necrotic areas.
CONCLUSIONS: Contrast-enhanced US-guided biopsy of solid abdominal and pelvic tumours in paediatric patients is an effective and safe procedure with greater diagnostic accuracy than US-guided biopsy, especially for tumours with necrotic areas.
CONCLUSIONS: Contrast-enhanced ultrasound (CEUS) may be superior to conventional ultrasound at guiding biopsy of abdominopelvic masses in paediatric patients. CEUS-guided core needle biopsy of abdominopelvic masses in children was safe and resulted in a diagnostic yield of 98.7%. CEUS guidance should be considered in this population when colour Doppler US is unable to determine a biopsy site.
METHODS: Patients aged < 18 years with abdominopelvic tumours who underwent either CEUS-GB or US-GB between April 2005 and May 2022 were retrospectively evaluated. Tumours diagnosed as malignancies by pathology were considered true-positive findings. Benign lesions were identified by pathology or clinical follow-up of at least 6 months. The diagnostic performance of the two groups was compared using propensity score matching (PSM). Complications were also analysed.
RESULTS: The present study included 764 paediatric patients (437 boys; median age, 24 months; interquartile range, 10-60 months); 151 were in the CEUS-GB group, and 613 were in the US-GB group. The sample adequacy rate was 100% (151 of 151) for the CEUS-GB group, which was greater than the 97.4% (597 of 613) for the US-GB group (p < 0.001). The overall diagnostic accuracy of the CEUS-GB group and US-GB group was 98.7% (149 of 151) versus 97.3% (581 of 597) in the total cohort (p = 0.551) and 98.7% (149 of 151) versus 92.7% (140 of 151) in the PSM cohort (p = 0.020). Two patients (0.3%) in the US-GB group experienced complications (Common Terminology Criteria for Adverse Events (CTCAE), grade 1-2) correlated with the biopsy. No adverse reactions occurred in the CEUS-GB group.
CONCLUSIONS: CEUS-GB of abdominopelvic tumours in paediatric patients is an effective and safe procedure with greater diagnostic accuracy than US-GB, especially for tumours with necrotic areas.
CONCLUSIONS: Contrast-enhanced US-guided biopsy of solid abdominal and pelvic tumours in paediatric patients is an effective and safe procedure with greater diagnostic accuracy than US-guided biopsy, especially for tumours with necrotic areas.
CONCLUSIONS: Contrast-enhanced ultrasound (CEUS) may be superior to conventional ultrasound at guiding biopsy of abdominopelvic masses in paediatric patients. CEUS-guided core needle biopsy of abdominopelvic masses in children was safe and resulted in a diagnostic yield of 98.7%. CEUS guidance should be considered in this population when colour Doppler US is unable to determine a biopsy site.
摘要：
目的：比较CEUS引导下活检（CEUS-GB）和超声引导下活检（US-GB）在评估小儿腹部和盆腔（腹盆腔）肿瘤中的诊断性能。
方法：在2005年4月至2022年5月期间接受CEUS-GB或US-GB治疗的年龄<18岁的腹盆腔肿瘤患者进行回顾性评估。通过病理学诊断为恶性肿瘤的肿瘤被认为是真阳性结果。通过病理或至少6个月的临床随访确定良性病变。使用倾向评分匹配（PSM）比较两组的诊断性能。并发症也进行了分析。
结果：本研究包括764名儿科患者（437名男孩；中位年龄，24个月；四分位数范围，10-60个月）；CEUS-GB组151人，613人属于US-GB组。CEUS-GB组的样本充足率为100％（151/151），高于US-GB组的97.4%(613个中的597个)(p<0.001)。CEUS-GB组和US-GB组的总诊断准确率分别为98.7%（151个中的149个）和97.3%（581个中的597个）（p=0.551），PSM组（p=0.020）分别为98.7%（151个中的149个）和92.7%（151个中的140个）。US-GB组中有两名患者（0.3％）出现并发症（不良事件通用术语标准（CTCAE），1-2级）与活检相关。CEUS-GB组无不良反应发生。
结论：CEUS-GB用于儿科患者腹肾盂肿瘤是一种有效且安全的方法，诊断准确性高于US-GB，特别是对于有坏死区域的肿瘤。
结论：小儿腹部和盆腔实性肿瘤的超声引导活检是一种有效且安全的方法，诊断准确性高于超声引导活检。特别是对于有坏死区域的肿瘤。
结论：超声造影（CEUS）在指导小儿腹盆腔肿块活检方面可能优于常规超声。CEUS引导下对儿童腹盆腔肿块进行芯针活检是安全的，诊断率为98.7％。当彩色多普勒超声无法确定活检部位时，应在该人群中考虑超声造影指导。
方法：在2005年4月至2022年5月期间接受CEUS-GB或US-GB治疗的年龄<18岁的腹盆腔肿瘤患者进行回顾性评估。通过病理学诊断为恶性肿瘤的肿瘤被认为是真阳性结果。通过病理或至少6个月的临床随访确定良性病变。使用倾向评分匹配（PSM）比较两组的诊断性能。并发症也进行了分析。
结果：本研究包括764名儿科患者（437名男孩；中位年龄，24个月；四分位数范围，10-60个月）；CEUS-GB组151人，613人属于US-GB组。CEUS-GB组的样本充足率为100％（151/151），高于US-GB组的97.4%(613个中的597个)(p<0.001)。CEUS-GB组和US-GB组的总诊断准确率分别为98.7%（151个中的149个）和97.3%（581个中的597个）（p=0.551），PSM组（p=0.020）分别为98.7%（151个中的149个）和92.7%（151个中的140个）。US-GB组中有两名患者（0.3％）出现并发症（不良事件通用术语标准（CTCAE），1-2级）与活检相关。CEUS-GB组无不良反应发生。
结论：CEUS-GB用于儿科患者腹肾盂肿瘤是一种有效且安全的方法，诊断准确性高于US-GB，特别是对于有坏死区域的肿瘤。
结论：小儿腹部和盆腔实性肿瘤的超声引导活检是一种有效且安全的方法，诊断准确性高于超声引导活检。特别是对于有坏死区域的肿瘤。
结论：超声造影（CEUS）在指导小儿腹盆腔肿块活检方面可能优于常规超声。CEUS引导下对儿童腹盆腔肿块进行芯针活检是安全的，诊断率为98.7％。当彩色多普勒超声无法确定活检部位时，应在该人群中考虑超声造影指导。
